Quince Therapeutics (QNCX) Competitors $1.60 -0.01 (-0.62%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 09/19/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. DSGN, DRUG, RCKT, IMAB, TECX, CTMX, ABEO, CGC, LRMR, and ALDXShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Design Therapeutics (DSGN), Bright Minds Biosciences (DRUG), Rocket Pharmaceuticals (RCKT), I-Mab (IMAB), Tectonic Therapeutic (TECX), CytomX Therapeutics (CTMX), Abeona Therapeutics (ABEO), Canopy Growth (CGC), Larimar Therapeutics (LRMR), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Its Competitors Design Therapeutics Bright Minds Biosciences Rocket Pharmaceuticals I-Mab Tectonic Therapeutic CytomX Therapeutics Abeona Therapeutics Canopy Growth Larimar Therapeutics Aldeyra Therapeutics Quince Therapeutics (NASDAQ:QNCX) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations. Is QNCX or DSGN more profitable? Design Therapeutics' return on equity of -27.15% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -187.49% -42.47% Design Therapeutics N/A -27.15%-26.07% Which has more volatility & risk, QNCX or DSGN? Quince Therapeutics has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Does the media prefer QNCX or DSGN? In the previous week, Design Therapeutics had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 1 mentions for Design Therapeutics and 0 mentions for Quince Therapeutics. Design Therapeutics' average media sentiment score of 1.87 beat Quince Therapeutics' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Quince Therapeutics Neutral Design Therapeutics Very Positive Do insiders & institutionals have more ownership in QNCX or DSGN? 30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 20.3% of Quince Therapeutics shares are held by insiders. Comparatively, 23.5% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, QNCX or DSGN? Design Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$56.83M-$1.09-1.47Design TherapeuticsN/AN/A-$49.59M-$1.12-5.40 Do analysts prefer QNCX or DSGN? Quince Therapeutics presently has a consensus price target of $8.14, suggesting a potential upside of 408.93%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Quince Therapeutics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryDesign Therapeutics beats Quince Therapeutics on 8 of the 14 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.48M$3.16B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-1.4720.6576.6126.78Price / SalesN/A446.54532.08124.24Price / CashN/A46.0037.9261.55Price / Book2.329.6613.746.40Net Income-$56.83M-$53.02M$3.30B$271.71M7 Day PerformanceN/A3.11%2.65%3.47%1 Month Performance-1.84%7.56%6.04%9.90%1 Year Performance84.91%11.15%80.14%28.50% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics3.1426 of 5 stars$1.60-0.6%$8.14+408.9%+110.5%$86.48MN/A-1.4760High Trading VolumeDSGNDesign Therapeutics0.3163 of 5 stars$5.86-2.8%N/A+3.2%$343.40MN/A-5.2340DRUGBright Minds Biosciences3.257 of 5 stars$48.66-0.2%$81.00+66.5%+4,184.0%$343.39MN/A-52.32N/AAnalyst UpgradeRCKTRocket Pharmaceuticals4.8068 of 5 stars$3.22+1.9%$16.73+419.7%-85.6%$340.98MN/A-1.28240Short Interest ↑IMABI-Mab2.4001 of 5 stars$3.62-11.5%$7.00+93.4%+241.4%$333.99M$3.89M0.00380Analyst DowngradeTECXTectonic Therapeutic3.1255 of 5 stars$16.59-6.4%$80.29+383.9%-24.3%$331.58MN/A-4.11120Positive NewsCTMXCytomX Therapeutics4.1403 of 5 stars$1.99-0.5%$5.75+188.9%+69.2%$329.83M$138.10M3.55170News CoverageAnalyst UpgradeABEOAbeona Therapeutics4.0783 of 5 stars$5.72-11.0%$19.50+240.9%-7.2%$329.72M$400K8.1790Positive NewsHigh Trading VolumeCGCCanopy Growth0.9374 of 5 stars$1.39+1.5%N/A-70.9%$328.59M$225.65M-0.463,150Positive NewsOptions VolumeLRMRLarimar Therapeutics2.631 of 5 stars$3.96+0.8%$18.43+365.4%-41.2%$325.32MN/A-2.5430ALDXAldeyra Therapeutics1.3343 of 5 stars$5.09-5.6%$9.50+86.6%-18.4%$322.84MN/A-5.9910High Trading Volume Related Companies and Tools Related Companies Design Therapeutics Alternatives Bright Minds Biosciences Alternatives Rocket Pharmaceuticals Alternatives I-Mab Alternatives Tectonic Therapeutic Alternatives CytomX Therapeutics Alternatives Abeona Therapeutics Alternatives Canopy Growth Alternatives Larimar Therapeutics Alternatives Aldeyra Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free QNCX Stock Alerts